review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters To Be Considered: The agenda will include discussions on additional doses of COVID–19 vaccine, including booster doses. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit *https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.*

Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: *http://www.cdc.gov/vaccines/acip/index.html.*

Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on *https://www.regulations.gov.* Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket.

Written Public Comment: Written comments must be received on or before August 24, 2021.

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP's Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

Procedure for Oral Public Comment: All persons interested in making an oral public comment at the August 24, 2021, ACIP meeting must submit a request at *http://www.cdc.gov/vaccines/acip/meetings/* no later than 11:59 p.m., EDT, August 22, 2021, according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by 12:00 p.m., EDT, August 23, 2021. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–17808 Filed 8–16–21; 4:15 pm]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Grant To Fund Task Force for Global Health, Inc.

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS) announces the award of approximately $47,000,000 in COVID–19 funding with an expected total funding of $100,000,000 over a five-year period to the Task Force for Global Health to expand the influenza and COVID–19 vaccine coverage in low- and middle-income countries.

DATES: The period for this award will be September 30, 2021 through September 29, 2026.

FOR FURTHER INFORMATION CONTACT: Archana Kumar, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–H24–8, Atlanta, GA 30329, Telephone: 800–232–6348, E-Mail: *eocevent445@cdc.gov.*

SUPPLEMENTARY INFORMATION: The single-source award will introduce and/or expand influenza vaccine programs, contribute to evidence base for influenza control and prevention, and leverage efforts to deploy pandemic vaccines to low- and middle-income countries.

The Task Force for Global Health will be awarded as a single-source because of their specific experience collaborating with multiple partners in facilitating the use of influenza vaccines in low- to middle-income countries and in developing local and global evidence base for sustained use of lifesaving vaccines since 2014. The Task Force for Global Health is uniquely qualified to support countries to plan for, implement and evaluate COVID–19 vaccination programs since they are currently working with the same risk groups using established tools and platforms under an existing cooperative agreement. The Task Force for Global Health leads the Partnership for Influenza Vaccine Introduction which includes ministries of health from 15 countries, private industry, and the United Nations International Children's Emergency Fund. This Partnership creates sustainable, seasonal influenza vaccination programs in the targeted countries, works with the World Health Organization to prepare for pandemic influenza, and supports countries' efforts to control and prevent seasonal outbreaks.

Summary of the Award

Recipient: The Task Force For Global Health.

Purpose of the Award: The purpose of award is to expand the use of influenza and COVID–19 vaccines in low- and middle-income countries (LMICs), support influenza vaccine introduction through a public-private partnership, establish an evidence base for global vaccine introduction decisions, and leverage this partnership to support readiness for and deployment of future pandemic vaccines. The recipient will be expected to assist partner countries

to plan, implement, and evaluate vaccination programs for influenza and COVID–19.

Amount of Award: $47,000,000 in Federal Fiscal Year (FFY) 2021 funds, and an estimated total of $100,000,000 over the five-year period of performance, subject to availability of funds.

Period of Performance: September 30, 2021 through September 29, 2026.

Authority: Section 307 of the Public Health Service Act, as amended (42 U.S.C. 242l).

Dated: August 12, 2021.

Joseph I. Hungate III,

Deputy Director, Office of Financial Resources, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–17678 Filed 8–17–21; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Notice of Meeting

AGENCY: Office on Trafficking in Persons, Administration for Children and Families, Department of Health and Human Services.

ACTION: Announcement of meeting and call for public comments on states' efforts to improve the nation's response to the sex trafficking of children and youth.

SUMMARY: Notice is hereby given, pursuant to the provisions of the Federal Advisory Committee Act (FACA) and the Preventing Sex Trafficking and Strengthening Families Act, that a meeting of the National Advisory Committee on the Sex Trafficking of Children and Youth in the United States (the Committee) will be held on September 8 and 9, 2021. The purpose of the meeting is for the Committee to begin reviewing responses to the Committee's State Self-Assessment Survey and develop a framework for the Committee's final report. The members of the Committee request comments from the public to inform their ongoing work and final report. Please submit your comments to *NAC@nhttac.org* with the subject ''NAC Comments'' as soon as possible and before September 6, 2021.

DATES: The meeting will be held on September 8 and 9, 2021.

ADDRESSES: The meeting will be held virtually. Please register for this event online: *https://www.acf.hhs.gov/otip/partnerships/national-advisory-committee.*

FOR FURTHER INFORMATION, CONTACT: Katherine Chon (Designated Federal Officer) at *EndTrafficking@acf.hhs.gov* or (202) 205–5778, or 330 C Street SW, Washington, DC 20201. Additional information is available at *https://www.acf.hhs.gov/otip/partnerships/the-national-advisory-committee.*

SUPPLEMENTARY INFORMATION: The formation and operation on behalf of the Committee are governed by the provisions of Public Law 92–463, as amended (5 U.S.C. App. 2), which sets forth standards for the formation and use of federal advisory committees.

Purpose of the Committee: The purpose of the Committee is to advise the Secretary and the Attorney General on practical and general policies concerning improvements to the nation's response to the sex trafficking of children and youth in the United States. HHS established the Committee pursuant to Section 121 of the Preventing Sex Trafficking and Strengthening Families Act of 2014 (Pub. L. 113–183).

Tentative Agenda: The agenda can be found at *https://www.acf.hhs.gov/otip/partnerships/the-national-advisory-committee.* To submit written statements, email *NAC@nhttac.org,* by September 6, 2021. Please include your name, organization, and phone number. More details on these options are below.

Public Accessibility to the Meeting: Pursuant to 5 U.S.C. 552b and 41 CFR 102–3.140 through 102–3.165, and subject to the availability of space, this meeting is open to the public virtually.

Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140 and section 10(a)(3) of the Federal Advisory Committee Act, the public may submit written statements in response to the stated agenda of the meeting, or to the Committee's mission, in general. Organizations with recommendations on strategies to engage states and stakeholders are encouraged to submit their comments or resources (hyperlinks preferred). Written comments or statements received after September 6, 2021, may not be provided to the Committee until its next meeting.

Verbal Statements: Pursuant to 41 CFR 102–3.140d, the Committee is not obligated to allow a member of the public to speak or otherwise address the Committee during the meeting. Members of the public are invited to provide verbal statements during the Committee meeting only at the time and manner described in the agenda. The request to speak should include a brief statement of the subject matter to be addressed and should be relevant to the stated agenda of the meeting or the Committee's mission in general.

Minutes: The minutes of this meeting will be available for public review and copying within 90 days at: *https://www.acf.hhs.gov/otip/partnerships/the-national-advisory-committee.*

Linda Hitt,

Director, Executive Secretariat.

[FR Doc. 2021–17714 Filed 8–17–21; 8:45 am]

BILLING CODE 4184–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240–669–5299; *elizabeth.pitts@nih.gov.* Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows.

Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line

Description of Technology

Worldwide, 130–150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the